Phenomex stock.
Discover historical prices for CELL stock on Yahoo Finance. View daily, weekly or monthly format back to when PhenomeX Inc. stock was issued.
PhenomeX Inc. (Nasdaq: CELL), a functional cell biology company, today announced it will showcase their latest optofluidic and proteomic technologies, along with customer partners, at two upcoming ...All Outstanding Shares of Common Stock . of . PHENOMEX INC. at $1.00 per share, net in cash, without interest . Pursuant to the Offer to Purchase dated August 31, 2023 . by . BIRD MERGERSUB CORPORATION . a wholly-owned subsidiary . of . BRUKER CORPORATIONJun. 28, 2023 at 9:41 a.m. ET on Baystreet.ca. CELL | Complete Grid Battery Metals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full …WebAre you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.
Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.
Xenetic Biosciences (XBIOW) has had the highest return since November 28, 2022 by a US stock, returning 111900%.The combined company, which will be named PhenomeX (Nasdaq: CELL), will be a premier functional cell biology company that provides live cell biology research tools which deliver deep insights into ...
PhenomeX Inc., formerly Berkeley Lights, Inc., is a functional cell biology company. The Company enables scientists to leverage each cell and drive the next generation of functional cell biology that will advance human health.Net Income. Shares Outstanding. PhenomeX Inc. eps - earnings per share from 2020 to 2023. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants. PhenomeX Inc. Annual EPS. 2022. $-1.42. 2021.EMERYVILLE, Calif., Sept. 5, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL) today announced that Bruker Corporation (Nasdaq: BRKR) has commenced, through its wholly owned subsidiary, Bird Mergersub Corporation, a cash tender offer to purchase all outstanding shares of common stock of PhenomeX for $1.00 …BILLERICA, Mass. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) and PhenomeX Inc. (Nasdaq: CELL) today announced that they have signed a definitive agreement for Bruker ...Company profile page for PhenomeX Inc including stock price, company news, press releases, executives, board members, and contact information
Historical daily share price chart and data for PhenomeX Inc. from 2020 to 2023 adjusted for splits and dividends. CELL was delisted after September 29, 2023. The latest closing stock price for PhenomeX Inc. on September 29, 2023 is 1.00. The all-time high PhenomeX Inc. closing stock price was 106.00 on December 22, 2020.
Under the terms of the merger agreement entered into on December 21, 2022, IsoPlexis shareholders received, for each share of IsoPlexis stock, 0.612 shares of Berkeley Lights common stock (which will be automatically converted into shares of PhenomeX common stock). With the transaction complete, former Berkeley Lights and IsoPlexis shareholders ...
On March 21, 2023 and in connection with the closing of the Merger, PhenomeX, IsoPlexis and Perceptive Credit Holdings III, LP (“ Perceptive ”) executed a Warrant Certificate (the “ Warrant Certificate ”). ). Under the Warrant Certificate, the outstanding warrant (the “ IsoPlexis Warrant ”) to purchase shares of common stock, par value $0.001, of IsoPlexis …Oct 3, 2023 · During its Q3 2023 earnings release, Bruker will provide more details on the expected Q4 2023 effect from PhenomeX. Today, Bruker reconfirms its medium-term financial outlook as issued at its Investor Day in June 2023. As a result of the transaction closing, PhenomeX common stock will no longer be listed for trading on the Nasdaq Global Market. This Tender Offer Statement on Schedule TO relates solely to preliminary communications made before the commencement of a planned tender offer by Bird Mergersub Corporation, a Delaware corporation (“Purchaser”) and wholly owned subsidiary of Bruker Corporation, a Delaware corporation (“Bruker”), for all of the outstanding shares of common stock of PhenomeX Inc., a Delaware corporation ...(A) Strategies for helix structure nucleation with i and i+4 crosslinking using metal complexation (top) or double click cycloaddition (bottom). a Di-azidoalanine peptide was treated in aqueous buffer with bis alkynes 6–9, sodium ascorbate, CuSO 4, and bathophenanthroline disulfonic acid or on resin in DMF with CuI and DIEA.(B) Peptide …The fair value is based on 24,945,611 shares of PhenomeX common stock at $ 1.28 per share on March 21, 2023 issued to IsoPlexis stockholders. IsoPlexis stockholders received 0.612 shares of PhenomeX stock for each IsoPlexis share they held.
PhenomeX was formed earlier this year when cell analysis firm Berkeley Lights closed its acquisition of proteomics firm IsoPlexis for $57.8 million in stock. In Q1, the firm reported revenues of $18.5 million, down 8 percent year over year.The fair value is based on 24,945,611 shares of PhenomeX common stock at $ 1.28 per share on March 21, 2023 issued to IsoPlexis stockholders. IsoPlexis stockholders received 0.612 shares of PhenomeX stock for …All. News. Press Releases. Find the latest PhenomeX Inc. (CELL) stock quote, history, news and other vital information to help you with your stock trading and investing.PhenomeX Reports Second Quarter 2023 Financial Results and Provides Business Update PR Newswire - Mon Aug 14, 3:05PM CDT /PRNewswire/ -- PhenomeX, Inc. (Nasdaq: …WebSearch for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.Bird Mergersub Corporation, a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Bruker Corporation, a Delaware corporation (“Bruker”), is offering to purchase all of the outstanding shares of common stock, par value $0.00005 per share (the “Shares”), of PhenomeX Inc., a Delaware corporation (“PhenomeX”), for $1.00 per Share, net to …
TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.com
The newly combined company has been renamed PhenomeX and its common stock will begin trading on Nasdaq under the ticker symbol "CELL" at market …WebOct 3, 2023 · As a result of the transaction closing, PhenomeX common stock will no longer be listed for trading on the Nasdaq Global Market. Also, PhenomeX will soon be changing its name. 43.0%. -36.3%. Market Cap. The market value of a company, in total dollars, also called "market capitalization." Market cap is calculated by taking a company's price per share and multiplying it ...BILLERICA, Mass. & EMERYVILLE, Calif.--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) and PhenomeX Inc. (Nasdaq: CELL) today announced that they have signed a definitive agreement for Bruker to acquire PhenomeX for $1.00 per share in an all-cash transaction.The proposed acquisition values PhenomeX at a total …... PhenomeX Inc. Contract Categories: Mergers & Acquisitions - Merger Agreements ... Each share of common stock, par value $0.001 per share, of Merger Sub issued ...pursuant to which, after consummation of the Offer and the satisfaction or waiver of certain conditions, Purchaser will merge with and into PhenomeX pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, as amended (the “DGCL”), upon the terms and subject to the conditions set forth in the Merger Agreement, with PhenomeX continuing as the surviving corporation ... Sep 5, 2023 · PhenomeX. 05 Sep, 2023, 16:02 ET. EMERYVILLE, Calif., Sept. 5, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL) today announced that Bruker Corporation (Nasdaq: BRKR) has commenced, through its ...
18 ago 2023 ... Bruker will buy PhenomeX for $1 per share in the all-cash transaction, the companies said. Mark Munch, president of the Bruker NANO Group ...
CELL Stock 12 Months Forecast. Based on 5 Wall Street analysts offering 12 month price targets for PhenomeX in the last 3 months. The average price target is $1.00 with a high forecast of $1.00 and a low forecast of $1.00. The average price target represents a 0.19% change from the last price of $1.00.
Item 7.01. Regulation FD Disclosure. Berkeley Lights, Inc. is aware of certain well-publicized recent developments involving Silicon Valley Bank . The Company considers its own banking exposure to... | May 2, 2023Get the latest PhenomeX detailed stock quotes, stock trade data, stock price info, and performance analysis, including PhenomeX Stock investment advice, charts, stats and …WebForgot password ? RememberIn depth view into CELL (PhenomeX) stock including the latest price, news, dividend history, earnings information and financials. PhenomeX Inc (CELL) 0.9981 0.00 (0.00%) …WebBird Mergersub Corporation, a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Bruker Corporation, a Delaware corporation (“Bruker”), is offering to purchase all of the outstanding shares of common stock, par value $0.00005 per share (the “Shares”), of PhenomeX Inc., a Delaware corporation (“PhenomeX”), for $1.00 per Share, net to the seller in cash, without ... Dec 22, 2022 · Berkeley Lights (Nasdaq: BLI), a life sciences tools company, and IsoPlexis (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire IsoPlexis in an all-stock transaction valued at $57.8 million. View %COMPANY_NAME% CELL investment & stock information. Get the latest %COMPANY_NAME% CELL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Under the terms of the merger agreement entered into on December 21, 2022, IsoPlexis shareholders received, for each share of IsoPlexis stock, 0.612 shares of Berkeley Lights common stock (which will be automatically converted into shares of PhenomeX common stock). With the transaction complete, former Berkeley Lights and IsoPlexis shareholders ...
The removal of selected endocrine disrupter compounds (EDCs), namely estrone (E1), 17β-estradiol (E2), 17α-ethynylestradiol (EE2), bisphenol A (BPA) and 4-tert-octylphenol (4t-OP) from municipal wastewater was investigated using a sequencing batch biofilter granular reactor (SBBGR), a new technology for biological treatment based on …Aug 17, 2023 · BILLERICA, Mass. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) and PhenomeX Inc. (Nasdaq: CELL) today announced that they have signed a definitive agreement for Bruker ... PhenomeX Inc. stock performance at a glance Check PhenomeX Inc.’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. CELL Stock PerformanceAug 24, 2023 · As the completion of this deal is anticipated in early Q4 2023, an arbitrage window emerges, offering a potential return of around 8% with the current share price per PhenomeX stock of about $0.93. Instagram:https://instagram. gle amg 63swhere to buy penny stocks onlinebrite.co reviewssofi meaning Item 2.02. Results of Operations and Financial Condition On November 4, 2021, Berkeley Lights, Inc. issued a press release announcing the Company's financial results for the quarter ended September... | March 25, 2023 cash advance apps for social security recipientsmplx stock forecast Berkeley Lights, Inc. entered into a collaboration with ChemPartner Co., Ltd. focused on accelerating ChemPartner's monoclonal antibody discovery workflow utilizing the Beacon® Optofluidic platform.... how to invest in oil UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Ex...Operating expenses were $53.3 million, inclusive of $3.7 million of stock-based compensation, for the second quarter of 2023, compared to $38.5 million, inclusive of $6.6 million of stock-based ...